SG/CALL/NOVO-NORDISK B/1150/0.1/19.06.26 | Market Closed - Bid/Ask 02:57:30 2024-06-27 pm EDT | After market 03:37:29 pm | |||
| 2.38 EUR | 0.00% |
|
2.395 | +0.63% |
| Current month | +22.68% | ||
| 1 month | +15.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 2.38 | 0.00% |
| 24-06-26 | 2.38 | -2.06% |
| 24-06-25 | 2.43 | +6.11% |
| 24-06-24 | 2.29 | -1.29% |
| 24-06-21 | 2.32 | +2.20% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 02:57 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9CV6 |
| ISIN | DE000SU9CV64 |
| Date issued | 2024-02-14 |
| Strike | 1,150 kr |
| Maturity | 2026-06-19 (722 Days) |
| Parity | 10 : 1 |
| Emission price | 1.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.55 € |
|---|---|
| Lowest since issue | 1.55 € |
| Spread | 0.03 € |
| Spread % | 1.24% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.86%
- Stock Market
- Warrants
- Warrant
